Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
Phase 2
Terminated
NCT05025423
| Condition | Mantle Cell Lymphoma |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
|---|
| Status | Terminated |
|---|
| Enrollment | 7 participants |
|---|
| Interventions | Venetoclax Oral Tablet [Venclexta] |
|---|
| Start date | Jun 21, 2022 |
|---|
| Completion date | May 14, 2025 |
|---|
| Results posted | Jun 9, 2026 |
|---|
Summary
The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The primary objective of the trial is to determine whether the combination of venetoclax with rituximab in this patient population yields a clinically acceptable proportion of overall responses (ORR, assessed by PET/CT with Lugano criteria) without chemotherapy.
Overall Response Rate (ORR) After Four Cycles of Venetoclax and Rituximab.
120 days · Participants
| Venetoclax and Rituximab in Patients Over 60 Yrs Old With Previously Untreated Mantle Cell Lymphoma | 4 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.